–
AstraZeneca vaccine trial results It works against the South African strain of COVID.
Reuters reported on February 6 that AstraZeneca Company Developer of the vaccine against the South African strain of COVID-19 Together with the University of Oxford The results of the company’s vaccine trial against COVID-19 The South African mutant, or b.1351, is a collaboration between Witwater Rand University and the University of Oxford. A sample was used in the trial of 2,026, with half of whom were assigned to the vaccine (placibol) group.
AstraZeneca said the results of Phase I and II trials, which are small group trials, have found that the vaccines developed. Effective in preventing COVID-19 infection Mutant B. 1.351 From those with only mild symptoms to a limited extent None of the participants were hospitalized or died.
The trial is part of the AstraZeneca vaccine efficacy trial. The three strains of the worrisome mutants were British B. 1.1.7, B. 1.351 from South Africa and P. 1. from Brazil. Patients with severe illness Preliminary AstraZeneca remains confident that Can prevent infection Considering antibodies to inhibit COVID-19 That the vaccine stimulates to occur in the body
Earlier, an AstraZeneca spokesperson said its vaccine would be tested against all the new mutants to prepare the vaccine to be prepared to tackle the new ones. And ready for release at the end of this year
–
–
Adhere to every situation from
Line @Matichon Get it here
–
–
